DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01046721

CompletedPhase NA

Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms

Investigation of the Cardiovascular Effects of Exenatide in Healthy Male Subjects

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

8

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 20-27•Male

Primary endpoint

•Superior mesenteric (SMA) blood flow

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01046721
Org study IDA/6/2009-exenatide-CVS

Timeline

Milestones

Study first posted2010-01-12estimated
Last update posted2018-03-06actual
Study start2009-09 (month precision)
Primary completion2012-12actual (month precision)
Study completion2012-12actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years
Maximum age45 Years
SexMale
Healthy volunteersAccepted

Inclusion criteria

•male,
•non-obese (BMI 20-27: those with a BMI > 25 will be excluded if they have a waist circumference > 90cm),
•aged 18-45yrs,
•non-smoker.

Exclusion criteria

•any metabolic or endocrine abnormalities,
•clinically significant abnormalities on screening,
•taking regular medication.

Endpoints (6)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Cardiometabolic biomarkers
4
Other (unclassified)
2

Cardiometabolic biomarkers

4 endpoints
Primary/protocol endpoint/low confidence

superior mesenteric (SMA) blood flow

Time frame:0, 30, 60, 90, 120, 150, & 180 min after meal

change from baseline, descriptive

Secondary/protocol endpoint

Blood Pressure (BP)

Time frame:0, 30, 60, 90, 120, 150, & 180 min after meal

descriptive, improvement

Secondary/protocol endpoint

Heart Rate (HR)

Time frame:0, 30, 60, 90, 120, 150, & 180 min after meal

Heart rate, change

change from baseline, improvement

Secondary/protocol endpoint/low confidence

Peripheral resistance

Time frame:0, 30, 60, 90, 120, 150, & 180 min after meal

descriptive

Other (unclassified)

2 endpoints
Secondary/protocol endpoint/low confidence

Limb Blood Flow (LBF)

Time frame:0, 30, 60, 90, 120, 150, & 180 min after meal

descriptive

Secondary/protocol endpoint/low confidence

Skin Blood Flow

Time frame:0, 30, 60, 90, 120, 150, & 180 min after meal

descriptive

Publications (1)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.